$FNCH
Finch Therapeutics Group, Inc.

2023 Q4 Form 10-Q Financial Statement

#000095017023060651 Filed on November 08, 2023

View on sec.gov

Income Statement

Concept 2023 Q4 2023 Q3
Revenue $0.00 $0.00
YoY Change -100.0% -100.0%
Cost Of Revenue
YoY Change
Gross Profit
YoY Change
Gross Profit Margin
Selling, General & Admin $4.681M $3.740M
YoY Change -57.2% -60.98%
% of Gross Profit
Research & Development $0.00 $0.00
YoY Change -100.0% -100.0%
% of Gross Profit
Depreciation & Amortization $40.00K $60.00K
YoY Change -97.16% -95.73%
% of Gross Profit
Operating Expenses $4.681M $3.781M
YoY Change -82.99% -90.73%
Operating Profit -$3.781M
YoY Change -90.69%
Interest Expense $333.0K $390.0K
YoY Change 28.57% 766.67%
% of Operating Profit
Other Income/Expense, Net $1.000M $1.365M
YoY Change 105.76% 422.99%
Pretax Income -$3.041M -$2.416M
YoY Change -88.74% -94.02%
Income Tax $0.00 $0.00
% Of Pretax Income
Net Earnings -$3.041M -$2.416M
YoY Change -88.74% -94.02%
Net Earnings / Revenue
Basic Earnings Per Share -$1.51
Diluted Earnings Per Share -$1.89 -$1.51
COMMON SHARES
Basic Shares Outstanding 1.606M 1.605M
Diluted Shares Outstanding 1.605M

Balance Sheet

Concept 2023 Q4 2023 Q3
SHORT-TERM ASSETS
Cash & Short-Term Investments $25.12M $28.80M
YoY Change -64.63% -66.23%
Cash & Equivalents $25.12M $28.80M
Short-Term Investments
Other Short-Term Assets $723.0K $1.100M
YoY Change -78.54% -79.34%
Inventory
Prepaid Expenses
Receivables $0.00 $0.00
Other Receivables $0.00 $0.00
Total Short-Term Assets $25.85M $29.92M
YoY Change -65.33% -66.98%
LONG-TERM ASSETS
Property, Plant & Equipment $27.18M $637.0K
YoY Change 70.54% -96.31%
Goodwill
YoY Change
Intangibles
YoY Change
Long-Term Investments
YoY Change
Other Assets $2.348M $0.00
YoY Change -44.52% -100.0%
Total Long-Term Assets $29.53M $29.57M
YoY Change -66.6% -69.62%
TOTAL ASSETS
Total Short-Term Assets $25.85M $29.92M
Total Long-Term Assets $29.53M $29.57M
Total Assets $55.37M $59.49M
YoY Change -66.02% -68.35%
SHORT-TERM LIABILITIES
YoY Change
Accounts Payable $141.0K $357.0K
YoY Change -87.15% -66.32%
Accrued Expenses $3.943M $4.500M
YoY Change -70.99% -64.7%
Deferred Revenue
YoY Change
Short-Term Debt $0.00 $0.00
YoY Change
Long-Term Debt Due
YoY Change
Total Short-Term Liabilities $4.084M $4.879M
YoY Change -72.2% -64.67%
LONG-TERM LIABILITIES
Long-Term Debt $0.00 $0.00
YoY Change -100.0% -100.0%
Other Long-Term Liabilities $28.40M $0.00
YoY Change 16607.65% -100.0%
Total Long-Term Liabilities $28.40M $0.00
YoY Change 91.61% -100.0%
TOTAL LIABILITIES
Total Short-Term Liabilities $4.084M $4.879M
Total Long-Term Liabilities $28.40M $0.00
Total Liabilities $32.49M $33.68M
YoY Change -51.68% -49.81%
SHAREHOLDERS EQUITY
Retained Earnings -$350.4M -$347.4M
YoY Change 27.14% 39.71%
Common Stock $373.3M $373.2M
YoY Change 0.52% 0.99%
Preferred Stock
YoY Change
Treasury Stock (at cost)
YoY Change
Treasury Stock Shares
Shareholders Equity $22.89M $25.81M
YoY Change
Total Liabilities & Shareholders Equity $55.37M $59.49M
YoY Change -66.02% -68.35%

Cashflow Statement

Concept 2023 Q4 2023 Q3
OPERATING ACTIVITIES
Net Income -$3.041M -$2.416M
YoY Change -88.74% -94.02%
Depreciation, Depletion And Amortization $40.00K $60.00K
YoY Change -97.16% -95.73%
Cash From Operating Activities -$3.705M -$5.260M
YoY Change -74.04% -72.45%
INVESTING ACTIVITIES
Capital Expenditures -$10.00K $0.00
YoY Change -119.61% -100.0%
Acquisitions
YoY Change
Other Investing Activities $37.00K $20.00K
YoY Change
Cash From Investing Activities $47.00K $20.00K
YoY Change -192.16% -106.1%
FINANCING ACTIVITIES
Cash Dividend Paid
YoY Change
Common Stock Issuance & Retirement, Net
YoY Change
Debt Paid & Issued, Net
YoY Change
Cash From Financing Activities 5.000K 0.000
YoY Change -90.38% -100.0%
NET CHANGE
Cash From Operating Activities -3.705M -5.260M
Cash From Investing Activities 47.00K 20.00K
Cash From Financing Activities 5.000K 0.000
Net Change In Cash -3.653M -5.240M
YoY Change -74.4% -72.96%
FREE CASH FLOW
Cash From Operating Activities -$3.705M -$5.260M
Capital Expenditures -$10.00K $0.00
Free Cash Flow -$3.695M -$5.260M
YoY Change -74.2% -71.97%

Facts In Submission

Frame Concept Type Concept / XBRL Key Value Unit
dei Amendment Flag
AmendmentFlag
false
dei Entity Central Index Key
EntityCentralIndexKey
0001733257
dei Document Fiscal Period Focus
DocumentFiscalPeriodFocus
Q3
dei Current Fiscal Year End Date
CurrentFiscalYearEndDate
--12-31
CY2023Q3 us-gaap Commitments And Contingencies
CommitmentsAndContingencies
CY2022Q4 us-gaap Commitments And Contingencies
CommitmentsAndContingencies
dei Document Type
DocumentType
10-Q
dei Document Quarterly Report
DocumentQuarterlyReport
true
dei Document Period End Date
DocumentPeriodEndDate
2023-09-30
dei Document Fiscal Year Focus
DocumentFiscalYearFocus
2023
dei Document Transition Report
DocumentTransitionReport
false
dei Entity File Number
EntityFileNumber
001-40227
dei Entity Registrant Name
EntityRegistrantName
FINCH THERAPEUTICS GROUP, INC.
dei Entity Incorporation State Country Code
EntityIncorporationStateCountryCode
DE
dei Entity Tax Identification Number
EntityTaxIdentificationNumber
82-3433558
dei Entity Address Address Line1
EntityAddressAddressLine1
75 State Street
dei Entity Address Address Line2
EntityAddressAddressLine2
Suite 100
dei Entity Address City Or Town
EntityAddressCityOrTown
Boston
dei Entity Address State Or Province
EntityAddressStateOrProvince
MA
dei Entity Address Postal Zip Code
EntityAddressPostalZipCode
02109
dei City Area Code
CityAreaCode
617
dei Local Phone Number
LocalPhoneNumber
229-6499
dei Security12b Title
Security12bTitle
Common Stock, $0.001 par value per share
dei Trading Symbol
TradingSymbol
FNCH
dei Security Exchange Name
SecurityExchangeName
NASDAQ
dei Entity Current Reporting Status
EntityCurrentReportingStatus
Yes
dei Entity Interactive Data Current
EntityInteractiveDataCurrent
Yes
dei Entity Filer Category
EntityFilerCategory
Non-accelerated Filer
dei Entity Small Business
EntitySmallBusiness
true
dei Entity Emerging Growth Company
EntityEmergingGrowthCompany
true
dei Entity Ex Transition Period
EntityExTransitionPeriod
false
dei Entity Shell Company
EntityShellCompany
false
CY2023Q4 dei Entity Common Stock Shares Outstanding
EntityCommonStockSharesOutstanding
1605763
CY2023Q3 us-gaap Cash And Cash Equivalents At Carrying Value
CashAndCashEquivalentsAtCarryingValue
28779000
CY2022Q4 us-gaap Cash And Cash Equivalents At Carrying Value
CashAndCashEquivalentsAtCarryingValue
71038000
CY2023Q3 us-gaap Accounts Receivable Net Current
AccountsReceivableNetCurrent
0
CY2022Q4 us-gaap Accounts Receivable Net Current
AccountsReceivableNetCurrent
144000
CY2023Q3 us-gaap Prepaid Expense And Other Assets Current
PrepaidExpenseAndOtherAssetsCurrent
1140000
CY2022Q4 us-gaap Prepaid Expense And Other Assets Current
PrepaidExpenseAndOtherAssetsCurrent
3369000
CY2023Q3 us-gaap Assets Current
AssetsCurrent
29919000
CY2022Q4 us-gaap Assets Current
AssetsCurrent
74551000
CY2023Q3 us-gaap Property Plant And Equipment Net
PropertyPlantAndEquipmentNet
637000
CY2022Q4 us-gaap Property Plant And Equipment Net
PropertyPlantAndEquipmentNet
15936000
CY2023Q3 us-gaap Operating Lease Right Of Use Asset
OperatingLeaseRightOfUseAsset
26589000
CY2022Q4 us-gaap Operating Lease Right Of Use Asset
OperatingLeaseRightOfUseAsset
32752000
CY2023Q3 fnch In Process Research And Development
InProcessResearchAndDevelopment
0
CY2022Q4 fnch In Process Research And Development
InProcessResearchAndDevelopment
32900000
CY2023Q3 us-gaap Restricted Cash Noncurrent
RestrictedCashNoncurrent
2348000
CY2022Q4 us-gaap Restricted Cash Noncurrent
RestrictedCashNoncurrent
2568000
CY2023Q3 us-gaap Other Assets Noncurrent
OtherAssetsNoncurrent
0
CY2022Q4 us-gaap Other Assets Noncurrent
OtherAssetsNoncurrent
4232000
CY2023Q3 us-gaap Assets
Assets
59493000
CY2022Q4 us-gaap Assets
Assets
162939000
CY2023Q3 us-gaap Accounts Payable Current
AccountsPayableCurrent
357000
CY2022Q4 us-gaap Accounts Payable Current
AccountsPayableCurrent
1097000
CY2023Q3 fnch Accrued Expenses And Other Current Liabilities
AccruedExpensesAndOtherCurrentLiabilities
2551000
CY2022Q4 fnch Accrued Expenses And Other Current Liabilities
AccruedExpensesAndOtherCurrentLiabilities
10161000
CY2023Q3 us-gaap Operating Lease Liability Current
OperatingLeaseLiabilityCurrent
1971000
CY2022Q4 us-gaap Operating Lease Liability Current
OperatingLeaseLiabilityCurrent
3431000
CY2023Q3 us-gaap Liabilities Current
LiabilitiesCurrent
4879000
CY2022Q4 us-gaap Liabilities Current
LiabilitiesCurrent
14689000
CY2023Q3 us-gaap Deferred Income Tax Liabilities Net
DeferredIncomeTaxLiabilitiesNet
0
CY2022Q4 us-gaap Deferred Income Tax Liabilities Net
DeferredIncomeTaxLiabilitiesNet
3461000
CY2023Q3 us-gaap Long Term Debt Noncurrent
LongTermDebtNoncurrent
0
CY2022Q4 us-gaap Long Term Debt Noncurrent
LongTermDebtNoncurrent
14653000
CY2023Q3 us-gaap Operating Lease Liability Noncurrent
OperatingLeaseLiabilityNoncurrent
28801000
CY2022Q4 us-gaap Operating Lease Liability Noncurrent
OperatingLeaseLiabilityNoncurrent
34255000
CY2023Q3 us-gaap Other Liabilities Noncurrent
OtherLiabilitiesNoncurrent
0
CY2022Q4 us-gaap Other Liabilities Noncurrent
OtherLiabilitiesNoncurrent
170000
CY2023Q3 us-gaap Liabilities
Liabilities
33680000
CY2022Q4 us-gaap Liabilities
Liabilities
67228000
CY2023Q3 us-gaap Temporary Equity Par Or Stated Value Per Share
TemporaryEquityParOrStatedValuePerShare
0.001
CY2022Q4 us-gaap Temporary Equity Par Or Stated Value Per Share
TemporaryEquityParOrStatedValuePerShare
0.001
CY2023Q3 us-gaap Temporary Equity Shares Authorized
TemporaryEquitySharesAuthorized
10000000
CY2022Q4 us-gaap Temporary Equity Shares Authorized
TemporaryEquitySharesAuthorized
10000000
CY2023Q3 us-gaap Temporary Equity Shares Issued
TemporaryEquitySharesIssued
0
CY2022Q4 us-gaap Temporary Equity Shares Issued
TemporaryEquitySharesIssued
0
CY2023Q3 us-gaap Temporary Equity Shares Outstanding
TemporaryEquitySharesOutstanding
0
CY2022Q4 us-gaap Temporary Equity Shares Outstanding
TemporaryEquitySharesOutstanding
0
CY2023Q3 us-gaap Preferred Stock Value
PreferredStockValue
0
CY2022Q4 us-gaap Preferred Stock Value
PreferredStockValue
0
CY2023Q3 us-gaap Common Stock Par Or Stated Value Per Share
CommonStockParOrStatedValuePerShare
0.001
CY2022Q4 us-gaap Common Stock Par Or Stated Value Per Share
CommonStockParOrStatedValuePerShare
0.001
CY2023Q3 us-gaap Common Stock Shares Authorized
CommonStockSharesAuthorized
200000000
CY2022Q4 us-gaap Common Stock Shares Authorized
CommonStockSharesAuthorized
200000000
CY2023Q3 us-gaap Common Stock Shares Issued
CommonStockSharesIssued
1605034
CY2023Q3 us-gaap Common Stock Shares Outstanding
CommonStockSharesOutstanding
1605034
CY2022Q4 us-gaap Common Stock Shares Issued
CommonStockSharesIssued
1601717
CY2022Q4 us-gaap Common Stock Shares Outstanding
CommonStockSharesOutstanding
1601717
CY2023Q3 us-gaap Common Stock Value
CommonStockValue
2000
CY2022Q4 us-gaap Common Stock Value
CommonStockValue
2000
CY2023Q3 us-gaap Additional Paid In Capital Common Stock
AdditionalPaidInCapitalCommonStock
373165000
CY2022Q4 us-gaap Additional Paid In Capital Common Stock
AdditionalPaidInCapitalCommonStock
371350000
CY2023Q3 us-gaap Retained Earnings Accumulated Deficit
RetainedEarningsAccumulatedDeficit
-347354000
CY2022Q4 us-gaap Retained Earnings Accumulated Deficit
RetainedEarningsAccumulatedDeficit
-275641000
CY2023Q3 us-gaap Stockholders Equity
StockholdersEquity
25813000
CY2022Q4 us-gaap Stockholders Equity
StockholdersEquity
95711000
CY2023Q3 us-gaap Liabilities And Stockholders Equity
LiabilitiesAndStockholdersEquity
59493000
CY2022Q4 us-gaap Liabilities And Stockholders Equity
LiabilitiesAndStockholdersEquity
162939000
CY2023Q3 us-gaap Revenue From Contract With Customer Excluding Assessed Tax
RevenueFromContractWithCustomerExcludingAssessedTax
0
CY2022Q3 us-gaap Revenue From Contract With Customer Excluding Assessed Tax
RevenueFromContractWithCustomerExcludingAssessedTax
138000
us-gaap Revenue From Contract With Customer Excluding Assessed Tax
RevenueFromContractWithCustomerExcludingAssessedTax
107000
us-gaap Revenue From Contract With Customer Excluding Assessed Tax
RevenueFromContractWithCustomerExcludingAssessedTax
853000
CY2023Q3 us-gaap Revenue From Contract With Customer Excluding Assessed Tax
RevenueFromContractWithCustomerExcludingAssessedTax
0
CY2022Q3 us-gaap Revenue From Contract With Customer Excluding Assessed Tax
RevenueFromContractWithCustomerExcludingAssessedTax
138000
us-gaap Revenue From Contract With Customer Excluding Assessed Tax
RevenueFromContractWithCustomerExcludingAssessedTax
107000
us-gaap Revenue From Contract With Customer Excluding Assessed Tax
RevenueFromContractWithCustomerExcludingAssessedTax
853000
CY2023Q3 us-gaap Research And Development Expense
ResearchAndDevelopmentExpense
0
CY2022Q3 us-gaap Research And Development Expense
ResearchAndDevelopmentExpense
11859000
us-gaap Research And Development Expense
ResearchAndDevelopmentExpense
7199000
us-gaap Research And Development Expense
ResearchAndDevelopmentExpense
41312000
CY2023Q3 us-gaap General And Administrative Expense
GeneralAndAdministrativeExpense
3735000
CY2022Q3 us-gaap General And Administrative Expense
GeneralAndAdministrativeExpense
9584000
us-gaap General And Administrative Expense
GeneralAndAdministrativeExpense
22229000
us-gaap General And Administrative Expense
GeneralAndAdministrativeExpense
27152000
CY2023Q3 us-gaap Goodwill And Intangible Asset Impairment
GoodwillAndIntangibleAssetImpairment
0
CY2022Q3 us-gaap Goodwill And Intangible Asset Impairment
GoodwillAndIntangibleAssetImpairment
-18057000
us-gaap Goodwill And Intangible Asset Impairment
GoodwillAndIntangibleAssetImpairment
0
us-gaap Goodwill And Intangible Asset Impairment
GoodwillAndIntangibleAssetImpairment
-18057000
CY2023Q3 fnch Impairment Of In Process Research And Development
ImpairmentOfInProcessResearchAndDevelopment
0
CY2022Q3 fnch Impairment Of In Process Research And Development
ImpairmentOfInProcessResearchAndDevelopment
0
fnch Impairment Of In Process Research And Development
ImpairmentOfInProcessResearchAndDevelopment
32900000
fnch Impairment Of In Process Research And Development
ImpairmentOfInProcessResearchAndDevelopment
0
CY2023Q3 us-gaap Impairment Of Long Lived Assets Held For Use
ImpairmentOfLongLivedAssetsHeldForUse
0
CY2022Q3 us-gaap Impairment Of Long Lived Assets Held For Use
ImpairmentOfLongLivedAssetsHeldForUse
0
us-gaap Impairment Of Long Lived Assets Held For Use
ImpairmentOfLongLivedAssetsHeldForUse
13141000
us-gaap Impairment Of Long Lived Assets Held For Use
ImpairmentOfLongLivedAssetsHeldForUse
0
CY2023Q3 us-gaap Restructuring Charges
RestructuringCharges
46000
CY2022Q3 us-gaap Restructuring Charges
RestructuringCharges
1270000
us-gaap Restructuring Charges
RestructuringCharges
4083000
us-gaap Restructuring Charges
RestructuringCharges
2173000
CY2023Q3 us-gaap Operating Expenses
OperatingExpenses
3781000
CY2022Q3 us-gaap Operating Expenses
OperatingExpenses
40770000
us-gaap Operating Expenses
OperatingExpenses
79552000
us-gaap Operating Expenses
OperatingExpenses
88694000
CY2023Q3 us-gaap Operating Income Loss
OperatingIncomeLoss
-3781000
CY2022Q3 us-gaap Operating Income Loss
OperatingIncomeLoss
-40632000
us-gaap Operating Income Loss
OperatingIncomeLoss
-79445000
us-gaap Operating Income Loss
OperatingIncomeLoss
-87841000
CY2023Q3 us-gaap Investment Income Net
InvestmentIncomeNet
392000
CY2022Q3 us-gaap Investment Income Net
InvestmentIncomeNet
45000
us-gaap Investment Income Net
InvestmentIncomeNet
1237000
us-gaap Investment Income Net
InvestmentIncomeNet
-7000
CY2023Q3 fnch Gain Loss On Lease Termination
GainLossOnLeaseTermination
0
CY2022Q3 fnch Gain Loss On Lease Termination
GainLossOnLeaseTermination
0
fnch Gain Loss On Lease Termination
GainLossOnLeaseTermination
752000
fnch Gain Loss On Lease Termination
GainLossOnLeaseTermination
0
CY2023Q3 us-gaap Gains Losses On Extinguishment Of Debt
GainsLossesOnExtinguishmentOfDebt
0
CY2022Q3 us-gaap Gains Losses On Extinguishment Of Debt
GainsLossesOnExtinguishmentOfDebt
0
us-gaap Gains Losses On Extinguishment Of Debt
GainsLossesOnExtinguishmentOfDebt
-1366000
us-gaap Gains Losses On Extinguishment Of Debt
GainsLossesOnExtinguishmentOfDebt
0
CY2023Q3 us-gaap Gain Loss On Disposition Of Assets1
GainLossOnDispositionOfAssets1
-22000
CY2022Q3 us-gaap Gain Loss On Disposition Of Assets1
GainLossOnDispositionOfAssets1
0
us-gaap Gain Loss On Disposition Of Assets1
GainLossOnDispositionOfAssets1
595000
us-gaap Gain Loss On Disposition Of Assets1
GainLossOnDispositionOfAssets1
-6000
CY2023Q3 us-gaap Other Nonoperating Income Expense
OtherNonoperatingIncomeExpense
995000
CY2022Q3 us-gaap Other Nonoperating Income Expense
OtherNonoperatingIncomeExpense
216000
us-gaap Other Nonoperating Income Expense
OtherNonoperatingIncomeExpense
3053000
us-gaap Other Nonoperating Income Expense
OtherNonoperatingIncomeExpense
216000
CY2023Q3 us-gaap Nonoperating Income Expense
NonoperatingIncomeExpense
1365000
CY2022Q3 us-gaap Nonoperating Income Expense
NonoperatingIncomeExpense
261000
us-gaap Nonoperating Income Expense
NonoperatingIncomeExpense
4271000
us-gaap Nonoperating Income Expense
NonoperatingIncomeExpense
203000
CY2023Q3 us-gaap Income Loss From Continuing Operations Before Income Taxes Extraordinary Items Noncontrolling Interest
IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest
-2416000
CY2022Q3 us-gaap Income Loss From Continuing Operations Before Income Taxes Extraordinary Items Noncontrolling Interest
IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest
-40371000
us-gaap Income Loss From Continuing Operations Before Income Taxes Extraordinary Items Noncontrolling Interest
IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest
-75174000
us-gaap Income Loss From Continuing Operations Before Income Taxes Extraordinary Items Noncontrolling Interest
IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest
-87638000
CY2023Q3 us-gaap Income Tax Expense Benefit
IncomeTaxExpenseBenefit
0
CY2022Q3 us-gaap Income Tax Expense Benefit
IncomeTaxExpenseBenefit
0
us-gaap Income Tax Expense Benefit
IncomeTaxExpenseBenefit
-3461000
us-gaap Income Tax Expense Benefit
IncomeTaxExpenseBenefit
0
CY2023Q3 us-gaap Net Income Loss
NetIncomeLoss
-2416000
CY2022Q3 us-gaap Net Income Loss
NetIncomeLoss
-40371000
us-gaap Net Income Loss
NetIncomeLoss
-71713000
us-gaap Net Income Loss
NetIncomeLoss
-87638000
CY2023Q3 us-gaap Earnings Per Share Basic
EarningsPerShareBasic
-1.51
CY2023Q3 us-gaap Earnings Per Share Diluted
EarningsPerShareDiluted
-1.51
CY2022Q3 us-gaap Earnings Per Share Diluted
EarningsPerShareDiluted
-25.38
CY2022Q3 us-gaap Earnings Per Share Basic
EarningsPerShareBasic
-25.38
us-gaap Earnings Per Share Basic
EarningsPerShareBasic
-44.7
us-gaap Earnings Per Share Diluted
EarningsPerShareDiluted
-44.7
us-gaap Earnings Per Share Diluted
EarningsPerShareDiluted
-55.22
us-gaap Earnings Per Share Basic
EarningsPerShareBasic
-55.22
CY2023Q3 us-gaap Weighted Average Number Of Shares Outstanding Basic
WeightedAverageNumberOfSharesOutstandingBasic
1604967
CY2023Q3 us-gaap Weighted Average Number Of Diluted Shares Outstanding
WeightedAverageNumberOfDilutedSharesOutstanding
1604967
CY2022Q3 us-gaap Weighted Average Number Of Shares Outstanding Basic
WeightedAverageNumberOfSharesOutstandingBasic
1590938
CY2022Q3 us-gaap Weighted Average Number Of Diluted Shares Outstanding
WeightedAverageNumberOfDilutedSharesOutstanding
1590938
us-gaap Weighted Average Number Of Shares Outstanding Basic
WeightedAverageNumberOfSharesOutstandingBasic
1604201
us-gaap Weighted Average Number Of Diluted Shares Outstanding
WeightedAverageNumberOfDilutedSharesOutstanding
1604201
us-gaap Weighted Average Number Of Shares Outstanding Basic
WeightedAverageNumberOfSharesOutstandingBasic
1587062
us-gaap Weighted Average Number Of Diluted Shares Outstanding
WeightedAverageNumberOfDilutedSharesOutstanding
1587062
CY2021Q4 us-gaap Stockholders Equity
StockholdersEquity
202224000
CY2022Q1 us-gaap Stock Issued During Period Value Stock Options Exercised
StockIssuedDuringPeriodValueStockOptionsExercised
14000
CY2022Q1 us-gaap Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value
AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
2120000
CY2022Q1 us-gaap Net Income Loss
NetIncomeLoss
-24567000
CY2022Q1 us-gaap Stockholders Equity
StockholdersEquity
179791000
CY2022Q2 us-gaap Stock Issued During Period Value Stock Options Exercised
StockIssuedDuringPeriodValueStockOptionsExercised
61000
CY2022Q2 us-gaap Stock Issued During Period Value Employee Stock Purchase Plan
StockIssuedDuringPeriodValueEmployeeStockPurchasePlan
110000
CY2022Q2 us-gaap Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value
AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
1830000
CY2022Q2 us-gaap Net Income Loss
NetIncomeLoss
-22700000
CY2022Q2 us-gaap Stockholders Equity
StockholdersEquity
159092000
CY2022Q3 us-gaap Stock Issued During Period Value Stock Options Exercised
StockIssuedDuringPeriodValueStockOptionsExercised
44000
CY2022Q3 us-gaap Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value
AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
2101000
CY2022Q3 us-gaap Net Income Loss
NetIncomeLoss
-40371000
CY2022Q3 us-gaap Stockholders Equity
StockholdersEquity
120866000
CY2022Q4 us-gaap Stockholders Equity
StockholdersEquity
95711000
CY2023Q1 us-gaap Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value
AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
1180000
CY2023Q1 us-gaap Net Income Loss
NetIncomeLoss
-62347000
CY2023Q1 us-gaap Stockholders Equity
StockholdersEquity
34544000
CY2023Q2 us-gaap Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value
AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
300000
CY2023Q2 us-gaap Net Income Loss
NetIncomeLoss
-6950000
CY2023Q2 us-gaap Stockholders Equity
StockholdersEquity
27894000
CY2023Q3 us-gaap Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value
AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
335000
CY2023Q3 us-gaap Net Income Loss
NetIncomeLoss
-2416000
CY2023Q3 us-gaap Stockholders Equity
StockholdersEquity
25813000
us-gaap Profit Loss
ProfitLoss
-71713000
us-gaap Profit Loss
ProfitLoss
-87638000
us-gaap Depreciation Depletion And Amortization
DepreciationDepletionAndAmortization
1476000
us-gaap Depreciation Depletion And Amortization
DepreciationDepletionAndAmortization
4099000
us-gaap Share Based Compensation
ShareBasedCompensation
1815000
us-gaap Share Based Compensation
ShareBasedCompensation
6051000
fnch Impairment Of In Process Research And Development
ImpairmentOfInProcessResearchAndDevelopment
32900000
fnch Impairment Of In Process Research And Development
ImpairmentOfInProcessResearchAndDevelopment
0
us-gaap Goodwill Impairment Loss
GoodwillImpairmentLoss
0
us-gaap Goodwill Impairment Loss
GoodwillImpairmentLoss
18057000
us-gaap Gains Losses On Extinguishment Of Debt
GainsLossesOnExtinguishmentOfDebt
-1366000
us-gaap Gains Losses On Extinguishment Of Debt
GainsLossesOnExtinguishmentOfDebt
0
us-gaap Impairment Of Long Lived Assets Held For Use
ImpairmentOfLongLivedAssetsHeldForUse
13141000
us-gaap Impairment Of Long Lived Assets Held For Use
ImpairmentOfLongLivedAssetsHeldForUse
0
us-gaap Gain Loss On Termination Of Lease
GainLossOnTerminationOfLease
752000
us-gaap Gain Loss On Termination Of Lease
GainLossOnTerminationOfLease
0
us-gaap Gain Loss On Sale Of Property Plant Equipment
GainLossOnSaleOfPropertyPlantEquipment
595000
us-gaap Gain Loss On Sale Of Property Plant Equipment
GainLossOnSaleOfPropertyPlantEquipment
-6000
fnch Non Cash Interest Expense
NonCashInterestExpense
2658000
fnch Non Cash Interest Expense
NonCashInterestExpense
2003000
us-gaap Deferred Income Tax Expense Benefit
DeferredIncomeTaxExpenseBenefit
-3461000
us-gaap Deferred Income Tax Expense Benefit
DeferredIncomeTaxExpenseBenefit
0
us-gaap Increase Decrease In Accounts Receivable
IncreaseDecreaseInAccountsReceivable
-144000
us-gaap Increase Decrease In Accounts Receivable
IncreaseDecreaseInAccountsReceivable
-494000
us-gaap Increase Decrease In Prepaid Deferred Expense And Other Assets
IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets
-2229000
us-gaap Increase Decrease In Prepaid Deferred Expense And Other Assets
IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets
4484000
us-gaap Increase Decrease In Other Noncurrent Assets
IncreaseDecreaseInOtherNoncurrentAssets
-4033000
us-gaap Increase Decrease In Other Noncurrent Assets
IncreaseDecreaseInOtherNoncurrentAssets
-656000
us-gaap Increase Decrease In Accounts Payable
IncreaseDecreaseInAccountsPayable
-740000
us-gaap Increase Decrease In Accounts Payable
IncreaseDecreaseInAccountsPayable
-2296000
us-gaap Increase Decrease In Accrued Liabilities And Other Operating Liabilities
IncreaseDecreaseInAccruedLiabilitiesAndOtherOperatingLiabilities
-7610000
us-gaap Increase Decrease In Accrued Liabilities And Other Operating Liabilities
IncreaseDecreaseInAccruedLiabilitiesAndOtherOperatingLiabilities
189000
us-gaap Increase Decrease In Other Noncurrent Liabilities
IncreaseDecreaseInOtherNoncurrentLiabilities
-50000
us-gaap Increase Decrease In Other Noncurrent Liabilities
IncreaseDecreaseInOtherNoncurrentLiabilities
50000
us-gaap Increase Decrease In Operating Lease Liability
IncreaseDecreaseInOperatingLeaseLiability
-2640000
us-gaap Increase Decrease In Operating Lease Liability
IncreaseDecreaseInOperatingLeaseLiability
2234000
us-gaap Net Cash Provided By Used In Operating Activities
NetCashProvidedByUsedInOperatingActivities
-27799000
us-gaap Net Cash Provided By Used In Operating Activities
NetCashProvidedByUsedInOperatingActivities
-60579000
us-gaap Proceeds From Sale Of Property Plant And Equipment
ProceedsFromSaleOfPropertyPlantAndEquipment
1290000
us-gaap Proceeds From Sale Of Property Plant And Equipment
ProceedsFromSaleOfPropertyPlantAndEquipment
0
us-gaap Payments To Acquire Property Plant And Equipment
PaymentsToAcquirePropertyPlantAndEquipment
14000
us-gaap Payments To Acquire Property Plant And Equipment
PaymentsToAcquirePropertyPlantAndEquipment
2131000
us-gaap Net Cash Provided By Used In Investing Activities
NetCashProvidedByUsedInInvestingActivities
1276000
us-gaap Net Cash Provided By Used In Investing Activities
NetCashProvidedByUsedInInvestingActivities
-2131000
us-gaap Proceeds From Stock Options Exercised
ProceedsFromStockOptionsExercised
0
us-gaap Proceeds From Stock Options Exercised
ProceedsFromStockOptionsExercised
229000
us-gaap Proceeds From Lines Of Credit
ProceedsFromLinesOfCredit
0
us-gaap Proceeds From Lines Of Credit
ProceedsFromLinesOfCredit
14738000
us-gaap Repayments Of Lines Of Credit
RepaymentsOfLinesOfCredit
15000000
us-gaap Repayments Of Lines Of Credit
RepaymentsOfLinesOfCredit
0
fnch Payment Of Terminal Fee Obligation And Prepayment Fee
PaymentOfTerminalFeeObligationAndPrepaymentFee
1155000
fnch Payment Of Terminal Fee Obligation And Prepayment Fee
PaymentOfTerminalFeeObligationAndPrepaymentFee
0
fnch Principal Payments On Capital Lease Obligation
PrincipalPaymentsOnCapitalLeaseObligation
0
fnch Principal Payments On Capital Lease Obligation
PrincipalPaymentsOnCapitalLeaseObligation
14000
us-gaap Payments Of Stock Issuance Costs
PaymentsOfStockIssuanceCosts
0
us-gaap Payments Of Stock Issuance Costs
PaymentsOfStockIssuanceCosts
132000
us-gaap Net Cash Provided By Used In Financing Activities
NetCashProvidedByUsedInFinancingActivities
-16155000
us-gaap Net Cash Provided By Used In Financing Activities
NetCashProvidedByUsedInFinancingActivities
14821000
us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Including Exchange Rate Effect
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect
-42678000
us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Including Exchange Rate Effect
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect
-47889000
CY2022Q4 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Including Disposal Group And Discontinued Operations
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations
73805000
CY2021Q4 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Including Disposal Group And Discontinued Operations
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations
135965000
CY2023Q3 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Including Disposal Group And Discontinued Operations
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations
31127000
CY2022Q3 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Including Disposal Group And Discontinued Operations
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations
88076000
us-gaap Capital Expenditures Incurred But Not Yet Paid
CapitalExpendituresIncurredButNotYetPaid
0
us-gaap Capital Expenditures Incurred But Not Yet Paid
CapitalExpendituresIncurredButNotYetPaid
106000
us-gaap Right Of Use Asset Obtained In Exchange For Operating Lease Liability
RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability
0
us-gaap Right Of Use Asset Obtained In Exchange For Operating Lease Liability
RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability
37094000
fnch Prepaid Rent Reclassified To Right Of Use Assets
PrepaidRentReclassifiedToRightOfUseAssets
0
fnch Prepaid Rent Reclassified To Right Of Use Assets
PrepaidRentReclassifiedToRightOfUseAssets
7736000
CY2023Q3 us-gaap Cash And Cash Equivalents At Carrying Value
CashAndCashEquivalentsAtCarryingValue
28779000
CY2022Q3 us-gaap Cash And Cash Equivalents At Carrying Value
CashAndCashEquivalentsAtCarryingValue
85292000
CY2023Q3 us-gaap Restricted Cash And Cash Equivalents
RestrictedCashAndCashEquivalents
2348000
CY2022Q3 us-gaap Restricted Cash And Cash Equivalents
RestrictedCashAndCashEquivalents
2784000
CY2023Q3 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Including Disposal Group And Discontinued Operations
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations
31127000
CY2022Q3 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Including Disposal Group And Discontinued Operations
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations
88076000
CY2023Q3 us-gaap Cash And Cash Equivalents At Carrying Value
CashAndCashEquivalentsAtCarryingValue
28800000
CY2023Q3 us-gaap Common Stock Par Or Stated Value Per Share
CommonStockParOrStatedValuePerShare
0.001
us-gaap Stock Issued During Period Shares Reverse Stock Splits
StockIssuedDuringPeriodSharesReverseStockSplits
30
CY2023Q3 fnch Transfers Between Fair Value Levels
TransfersBetweenFairValueLevels
0
CY2022Q4 fnch Transfers Between Fair Value Levels
TransfersBetweenFairValueLevels
0
us-gaap Operating Lease Cost
OperatingLeaseCost
3374000
CY2023Q3 us-gaap Short Term Lease Cost
ShortTermLeaseCost
0
CY2022Q3 us-gaap Short Term Lease Cost
ShortTermLeaseCost
18000
CY2023Q3 us-gaap Operating Leases Future Minimum Payments Due Thereafter
OperatingLeasesFutureMinimumPaymentsDueThereafter
22391000
CY2023Q3 us-gaap Operating Leases Future Minimum Payments Due
OperatingLeasesFutureMinimumPaymentsDue
43297000
CY2023Q3 fnch Interest Portion Of Operating Leases Future Minimum Payments Due
InterestPortionOfOperatingLeasesFutureMinimumPaymentsDue
-12525000
CY2023Q3 fnch Present Value Of Future Minimum Lease Payments
PresentValueOfFutureMinimumLeasePayments
30772000
CY2023Q3 us-gaap Property Plant And Equipment Gross
PropertyPlantAndEquipmentGross
869000
CY2022Q4 us-gaap Property Plant And Equipment Gross
PropertyPlantAndEquipmentGross
25222000
CY2023Q3 us-gaap Accumulated Depreciation Depletion And Amortization Property Plant And Equipment
AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment
232000
CY2022Q4 us-gaap Accumulated Depreciation Depletion And Amortization Property Plant And Equipment
AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment
9286000
CY2023Q3 us-gaap Property Plant And Equipment Net
PropertyPlantAndEquipmentNet
637000
CY2022Q4 us-gaap Property Plant And Equipment Net
PropertyPlantAndEquipmentNet
15936000
us-gaap Depreciation
Depreciation
1500000
us-gaap Depreciation
Depreciation
4100000
CY2023Q1 us-gaap Impairment Of Long Lived Assets To Be Disposed Of
ImpairmentOfLongLivedAssetsToBeDisposedOf
13100000
us-gaap Gain Loss On Sale Of Property Plant Equipment
GainLossOnSaleOfPropertyPlantEquipment
600000
CY2015Q4 fnch Lessee Operating Lease Leases Area
LesseeOperatingLeaseLeasesArea
25785
CY2023Q3 us-gaap Operating Lease Right Of Use Asset
OperatingLeaseRightOfUseAsset
26589000
CY2022Q4 us-gaap Operating Lease Right Of Use Asset
OperatingLeaseRightOfUseAsset
32752000
CY2023Q3 us-gaap Operating Lease Liability Current
OperatingLeaseLiabilityCurrent
1971000
CY2022Q4 us-gaap Operating Lease Liability Current
OperatingLeaseLiabilityCurrent
3431000
CY2023Q3 us-gaap Operating Lease Liability Noncurrent
OperatingLeaseLiabilityNoncurrent
28801000
CY2022Q4 us-gaap Operating Lease Liability Noncurrent
OperatingLeaseLiabilityNoncurrent
34255000
CY2023Q3 fnch Lease Liabilities
LeaseLiabilities
30772000
CY2022Q4 fnch Lease Liabilities
LeaseLiabilities
37686000
CY2023Q3 us-gaap Operating Lease Cost
OperatingLeaseCost
1382000
CY2022Q3 us-gaap Operating Lease Cost
OperatingLeaseCost
1724000
us-gaap Operating Lease Cost
OperatingLeaseCost
4783000
us-gaap Short Term Lease Cost
ShortTermLeaseCost
17000
us-gaap Short Term Lease Cost
ShortTermLeaseCost
157000
CY2023Q3 us-gaap Variable Lease Cost
VariableLeaseCost
60000
CY2022Q3 us-gaap Variable Lease Cost
VariableLeaseCost
481000
us-gaap Variable Lease Cost
VariableLeaseCost
592000
us-gaap Variable Lease Cost
VariableLeaseCost
1445000
CY2023Q3 us-gaap Sublease Income
SubleaseIncome
996000
CY2022Q3 us-gaap Sublease Income
SubleaseIncome
216000
us-gaap Sublease Income
SubleaseIncome
2914000
us-gaap Sublease Income
SubleaseIncome
216000
CY2023Q3 us-gaap Lease Cost
LeaseCost
446000
CY2022Q3 us-gaap Lease Cost
LeaseCost
2007000
us-gaap Lease Cost
LeaseCost
2478000
us-gaap Lease Cost
LeaseCost
4760000
CY2023Q3 us-gaap Operating Lease Weighted Average Remaining Lease Term1
OperatingLeaseWeightedAverageRemainingLeaseTerm1
P8Y3M18D
CY2022Q4 us-gaap Operating Lease Weighted Average Remaining Lease Term1
OperatingLeaseWeightedAverageRemainingLeaseTerm1
P8Y6M
CY2023Q3 us-gaap Operating Lease Weighted Average Discount Rate Percent
OperatingLeaseWeightedAverageDiscountRatePercent
0.085
CY2022Q4 us-gaap Operating Lease Weighted Average Discount Rate Percent
OperatingLeaseWeightedAverageDiscountRatePercent
0.083
us-gaap Increase Decrease In Operating Lease Liability
IncreaseDecreaseInOperatingLeaseLiability
-2640000
us-gaap Increase Decrease In Operating Lease Liability
IncreaseDecreaseInOperatingLeaseLiability
2234000
CY2023Q3 us-gaap Operating Leases Future Minimum Payments Due Current
OperatingLeasesFutureMinimumPaymentsDueCurrent
895000
CY2023Q3 us-gaap Operating Leases Future Minimum Payments Due In Two Years
OperatingLeasesFutureMinimumPaymentsDueInTwoYears
4795000
CY2023Q3 us-gaap Operating Leases Future Minimum Payments Due In Three Years
OperatingLeasesFutureMinimumPaymentsDueInThreeYears
4930000
CY2023Q3 us-gaap Operating Leases Future Minimum Payments Due In Four Years
OperatingLeasesFutureMinimumPaymentsDueInFourYears
5071000
CY2023Q3 us-gaap Operating Leases Future Minimum Payments Due In Five Years
OperatingLeasesFutureMinimumPaymentsDueInFiveYears
5215000
us-gaap Allocated Share Based Compensation Expense
AllocatedShareBasedCompensationExpense
1815000
us-gaap Allocated Share Based Compensation Expense
AllocatedShareBasedCompensationExpense
6051000
us-gaap Antidilutive Securities Excluded From Computation Of Earnings Per Share Amount
AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
153042
CY2023Q3 fnch Accrued Research And Development
AccruedResearchAndDevelopment
99000
CY2022Q4 fnch Accrued Research And Development
AccruedResearchAndDevelopment
1967000
CY2023Q3 us-gaap Accrued Professional Fees Current
AccruedProfessionalFeesCurrent
1630000
CY2022Q4 us-gaap Accrued Professional Fees Current
AccruedProfessionalFeesCurrent
5852000
CY2023Q3 us-gaap Accrued Employee Benefits Current
AccruedEmployeeBenefitsCurrent
7000
CY2022Q4 us-gaap Accrued Employee Benefits Current
AccruedEmployeeBenefitsCurrent
880000
CY2023Q3 us-gaap Other Accrued Liabilities Current
OtherAccruedLiabilitiesCurrent
815000
CY2022Q4 us-gaap Other Accrued Liabilities Current
OtherAccruedLiabilitiesCurrent
1462000
CY2023Q3 fnch Accrued Expenses And Other Current Liabilities
AccruedExpensesAndOtherCurrentLiabilities
2551000
CY2022Q4 fnch Accrued Expenses And Other Current Liabilities
AccruedExpensesAndOtherCurrentLiabilities
10161000
us-gaap Restructuring Charges
RestructuringCharges
4100000
us-gaap Antidilutive Securities Excluded From Computation Of Earnings Per Share Amount
AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
57804
CY2023Q3 us-gaap Preferred Stock Shares Outstanding
PreferredStockSharesOutstanding
0
us-gaap Common Stock Voting Rights
CommonStockVotingRights
Each share of common stock entitles the holder to one vote
us-gaap Dividends Common Stock Cash
DividendsCommonStockCash
0
CY2023Q3 us-gaap Common Stock Capital Shares Reserved For Future Issuance
CommonStockCapitalSharesReservedForFutureIssuance
57804
CY2022Q4 us-gaap Common Stock Capital Shares Reserved For Future Issuance
CommonStockCapitalSharesReservedForFutureIssuance
118564
CY2023Q3 us-gaap Allocated Share Based Compensation Expense
AllocatedShareBasedCompensationExpense
335000
CY2022Q3 us-gaap Allocated Share Based Compensation Expense
AllocatedShareBasedCompensationExpense
2101000
us-gaap Defined Contribution Plan Employer Discretionary Contribution Amount
DefinedContributionPlanEmployerDiscretionaryContributionAmount
100000
us-gaap Defined Contribution Plan Employer Discretionary Contribution Amount
DefinedContributionPlanEmployerDiscretionaryContributionAmount
600000
CY2023Q3 us-gaap Net Income Loss
NetIncomeLoss
-2416000
CY2022Q3 us-gaap Net Income Loss
NetIncomeLoss
-40371000
us-gaap Net Income Loss
NetIncomeLoss
-71713000
us-gaap Net Income Loss
NetIncomeLoss
-87638000
CY2023Q3 us-gaap Net Income Loss Available To Common Stockholders Basic
NetIncomeLossAvailableToCommonStockholdersBasic
-2416000
CY2023Q3 us-gaap Net Income Loss Available To Common Stockholders Diluted
NetIncomeLossAvailableToCommonStockholdersDiluted
-2416000
CY2022Q3 us-gaap Net Income Loss Available To Common Stockholders Basic
NetIncomeLossAvailableToCommonStockholdersBasic
-40371000
CY2022Q3 us-gaap Net Income Loss Available To Common Stockholders Diluted
NetIncomeLossAvailableToCommonStockholdersDiluted
-40371000
us-gaap Net Income Loss Available To Common Stockholders Basic
NetIncomeLossAvailableToCommonStockholdersBasic
-71713000
us-gaap Net Income Loss Available To Common Stockholders Diluted
NetIncomeLossAvailableToCommonStockholdersDiluted
-71713000
us-gaap Net Income Loss Available To Common Stockholders Basic
NetIncomeLossAvailableToCommonStockholdersBasic
-87638000
us-gaap Net Income Loss Available To Common Stockholders Diluted
NetIncomeLossAvailableToCommonStockholdersDiluted
-87638000
CY2023Q3 us-gaap Weighted Average Number Of Shares Outstanding Basic
WeightedAverageNumberOfSharesOutstandingBasic
1604967
CY2023Q3 us-gaap Weighted Average Number Of Diluted Shares Outstanding
WeightedAverageNumberOfDilutedSharesOutstanding
1604967
CY2022Q3 us-gaap Weighted Average Number Of Shares Outstanding Basic
WeightedAverageNumberOfSharesOutstandingBasic
1590938
CY2022Q3 us-gaap Weighted Average Number Of Diluted Shares Outstanding
WeightedAverageNumberOfDilutedSharesOutstanding
1590938
us-gaap Weighted Average Number Of Shares Outstanding Basic
WeightedAverageNumberOfSharesOutstandingBasic
1604201
us-gaap Weighted Average Number Of Diluted Shares Outstanding
WeightedAverageNumberOfDilutedSharesOutstanding
1604201
us-gaap Weighted Average Number Of Shares Outstanding Basic
WeightedAverageNumberOfSharesOutstandingBasic
1587062
us-gaap Weighted Average Number Of Diluted Shares Outstanding
WeightedAverageNumberOfDilutedSharesOutstanding
1587062
CY2023Q3 us-gaap Earnings Per Share Basic
EarningsPerShareBasic
-1.51
CY2023Q3 us-gaap Earnings Per Share Diluted
EarningsPerShareDiluted
-1.51
CY2022Q3 us-gaap Earnings Per Share Basic
EarningsPerShareBasic
-25.38
CY2022Q3 us-gaap Earnings Per Share Diluted
EarningsPerShareDiluted
-25.38
us-gaap Earnings Per Share Basic
EarningsPerShareBasic
-44.7
us-gaap Earnings Per Share Diluted
EarningsPerShareDiluted
-44.7
us-gaap Earnings Per Share Basic
EarningsPerShareBasic
-55.22
us-gaap Earnings Per Share Diluted
EarningsPerShareDiluted
-55.22

Files In Submission

Name View Source Status
FilingSummary.xml Edgar Link unprocessable
fnch-20230930_def.xml Edgar Link unprocessable
0000950170-23-060651-index-headers.html Edgar Link pending
0000950170-23-060651-index.html Edgar Link pending
0000950170-23-060651.txt Edgar Link pending
0000950170-23-060651-xbrl.zip Edgar Link pending
Financial_Report.xlsx Edgar Link pending
fnch-20230930.htm Edgar Link pending
fnch-20230930.xsd Edgar Link pending
fnch-ex31_1.htm Edgar Link pending
fnch-ex31_2.htm Edgar Link pending
fnch-ex32_1.htm Edgar Link pending
MetaLinks.json Edgar Link pending
R1.htm Edgar Link pending
R10.htm Edgar Link pending
R11.htm Edgar Link pending
R12.htm Edgar Link pending
R13.htm Edgar Link pending
R14.htm Edgar Link pending
R15.htm Edgar Link pending
R16.htm Edgar Link pending
R17.htm Edgar Link pending
R18.htm Edgar Link pending
R19.htm Edgar Link pending
R2.htm Edgar Link pending
R20.htm Edgar Link pending
R21.htm Edgar Link pending
R22.htm Edgar Link pending
R23.htm Edgar Link pending
R24.htm Edgar Link pending
R25.htm Edgar Link pending
R26.htm Edgar Link pending
R27.htm Edgar Link pending
R28.htm Edgar Link pending
R29.htm Edgar Link pending
fnch-20230930_htm.xml Edgar Link completed
R3.htm Edgar Link pending
R30.htm Edgar Link pending
R31.htm Edgar Link pending
R32.htm Edgar Link pending
R33.htm Edgar Link pending
R34.htm Edgar Link pending
R35.htm Edgar Link pending
R36.htm Edgar Link pending
R37.htm Edgar Link pending
R38.htm Edgar Link pending
R39.htm Edgar Link pending
R4.htm Edgar Link pending
R40.htm Edgar Link pending
R41.htm Edgar Link pending
R42.htm Edgar Link pending
R43.htm Edgar Link pending
R44.htm Edgar Link pending
R45.htm Edgar Link pending
R46.htm Edgar Link pending
R47.htm Edgar Link pending
R48.htm Edgar Link pending
R49.htm Edgar Link pending
R5.htm Edgar Link pending
R50.htm Edgar Link pending
R51.htm Edgar Link pending
R52.htm Edgar Link pending
R53.htm Edgar Link pending
R54.htm Edgar Link pending
R55.htm Edgar Link pending
R56.htm Edgar Link pending
R6.htm Edgar Link pending
R7.htm Edgar Link pending
R8.htm Edgar Link pending
R9.htm Edgar Link pending
report.css Edgar Link pending
Show.js Edgar Link pending
fnch-20230930_cal.xml Edgar Link unprocessable
fnch-20230930_pre.xml Edgar Link unprocessable
fnch-20230930_lab.xml Edgar Link unprocessable